Home » Topics » Deals and M&A » Collaboration

Collaboration
RSS

Lilly, Merck and Pfizer form Asian Cancer Research Group

Feb. 23, 2010

Viamet and Novartis partner for metalloenzyme inhibitors

Feb. 23, 2010

Ceragenix and BexPharm enter into agreement for EpiCeram

Feb. 23, 2010

Chugai licenses Roche's Hedgehog pathway inhibitor RG-3616 in Japan

Feb. 19, 2010

Thallion and LFB sign agreement to develop STEC infection therapy

Feb. 19, 2010

SurModics to terminate license agreement with Ambrilia Biopharma

Feb. 19, 2010

Paladin amends R&D agreement with Isotechnika for diagnostic products

Feb. 19, 2010

TD2 and Rondaxe sign alliance to help emerging companies develop cancer therapeutics

Feb. 18, 2010

MorphoSys and Galapagos add another antibody target to alliance in bone and joint diseases

Feb. 18, 2010

Lung Rx and ImmuneWorks sign development agreement for IW-001 in IPF and PGD

Feb. 17, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors
BioWorld Science
Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.
Empire Discovery Institute, Univ. of Rochester identify IRAK inhibitors
BioWorld Science
Empire Discovery Institute and the University of Rochester have discovered new interleukin-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 inhibitors...